BULENT OZPOLAT to Triple Negative Breast Neoplasms
This is a "connection" page, showing publications BULENT OZPOLAT has written about Triple Negative Breast Neoplasms.
Connection Strength
3.216
-
Therapeutic Landscape of AXL Receptor Kinase in Triple-Negative Breast Cancer. Mol Cancer Ther. 2023 07 05; 22(7):818-832.
Score: 0.456
-
Serotonin 5-HT7 receptor is a biomarker poor prognostic factor and induces proliferation of triple-negative breast cancer cells through FOXM1. Breast Cancer. 2022 Nov; 29(6):1106-1120.
Score: 0.429
-
MicroRNA profiling identifies Forkhead box transcription factor M1 (FOXM1) regulated miR-186 and miR-200b alterations in triple negative breast cancer. Cell Signal. 2021 07; 83:109979.
Score: 0.389
-
Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer. Breast Cancer Res Treat. 2018 Oct; 171(3):593-605.
Score: 0.322
-
Dual Suppressive Effect of miR-34a on the FOXM1/eEF2-Kinase Axis Regulates Triple-Negative Breast Cancer Growth and Invasion. Clin Cancer Res. 2018 09 01; 24(17):4225-4241.
Score: 0.319
-
FOXM1 transcriptionally regulates expression of integrin ?1 in triple-negative breast cancer. Breast Cancer Res Treat. 2017 Jun; 163(3):485-493.
Score: 0.295
-
MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase. Oncotarget. 2017 Feb 14; 8(7):11641-11658.
Score: 0.293
-
FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells. Oncotarget. 2016 Mar 29; 7(13):16619-35.
Score: 0.275
-
Translational Modeling Identifies Synergy between Nanoparticle-Delivered miRNA-22 and Standard-of-Care Drugs in Triple-Negative Breast Cancer. Pharm Res. 2022 Mar; 39(3):511-528.
Score: 0.104
-
Thymoquinone Inhibits Proliferation and Migration of MDA-MB-231 Triple Negative Breast Cancer Cells by Suppressing Autophagy, Beclin-1 and LC3. Anticancer Agents Med Chem. 2021; 21(3):355-364.
Score: 0.096
-
FOXM1 plays a role in autophagy by transcriptionally regulating Beclin-1 and LC3 genes in human triple-negative breast cancer cells. J Mol Med (Berl). 2019 04; 97(4):491-508.
Score: 0.084
-
Targeting LC3 and Beclin-1 autophagy genes suppresses proliferation, survival, migration and invasion by inhibition of Cyclin-D1 and uPAR/Integrin ?1/ Src signaling in triple negative breast cancer cells. J Cancer Res Clin Oncol. 2018 Mar; 144(3):415-430.
Score: 0.078
-
Modified gold-based siRNA nanotherapeutics for targeted therapy of triple-negative breast cancer. Nanomedicine (Lond). 2017 Aug; 12(16):1961-1973.
Score: 0.075